Ing Groep Nv Eli Lilly & CO Transaction History

Ing Groep Nv

$16.5 Billion
Q3 2024

A detailed history of Ing Groep Nv transactions in Eli Lilly & CO stock. As of the latest transaction made, Ing Groep Nv holds 4,302 shares of LLY stock, worth $3.35 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

4,302

Previous 118,726 96.38%

Holding current value

$3.35 Million

Previous $107 Million 96.45%

% of portfolio

0.02%

Previous 0.65%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$772.14 - $960.02 $88.4 Million - $110 Million	-114,424 Reduced 96.38%	4,302 $3.81 Million
Q2 2024 Aug 13, 2024	BUY	$724.87 - $909.04 $10.8 Million - $13.5 Million	14,856 Added 14.3%	118,726 $107 Million
Q1 2024 May 10, 2024	BUY	$592.2 - $792.28 $60.8 Million - $81.4 Million	102,701 Added 8785.37%	103,870 $80.8 Million
Q4 2023 Feb 08, 2024	SELL	$525.19 - $619.13 $52 Million - $61.3 Million	-98,939 Reduced 98.83%	1,169 $681,000
Q3 2023 Oct 27, 2023	SELL	$434.7 - $599.3 $40.2 Million - $55.4 Million	-92,442 Reduced 48.01%	100,108 $53.8 Million
Q2 2023 Aug 07, 2023	BUY	$350.74 - $468.98 $35 Million - $46.8 Million	99,736 Added 107.46%	192,550 $90.3 Million
Q1 2023 May 09, 2023	SELL	$310.63 - $364.82 $21.1 Million - $24.8 Million	-67,876 Reduced 42.24%	92,814 $31.9 Million
Q4 2022 Feb 10, 2023	BUY	$321.55 - $374.67 $11.9 Million - $13.9 Million	37,085 Added 30.0%	160,690 $58.8 Million
Q3 2022 Nov 14, 2022	SELL	$296.48 - $337.87 $7.35 Million - $8.38 Million	-24,799 Reduced 16.71%	123,605 $40 Million
Q2 2022 Aug 08, 2022	BUY	$278.73 - $327.27 $6.25 Million - $7.34 Million	22,436 Added 17.81%	148,404 $48.1 Million
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $4.99 Million - $6.2 Million	-21,259 Reduced 14.44%	125,968 $36.1 Million
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $17.9 Million - $22.2 Million	79,686 Added 117.98%	147,227 $40.7 Million
Q3 2021 Nov 02, 2021	BUY	$221.6 - $272.71 $284,091 - $349,614	1,282 Added 1.93%	67,541 $15.6 Million
Q2 2021 Aug 13, 2021	BUY	$180.55 - $233.54 $1.95 Million - $2.52 Million	10,795 Added 19.46%	66,259 $15.2 Million
Q1 2021 May 12, 2021	SELL	$164.32 - $212.72 $457,959 - $592,850	-2,787 Reduced 4.78%	55,464 $10.4 Million
Q4 2020 Feb 11, 2021	BUY	$130.46 - $172.63 $4.58 Million - $6.06 Million	35,093 Added 151.54%	58,251 $9.84 Million
Q3 2020 Nov 12, 2020	BUY	$146.22 - $169.13 $65,214 - $75,431	446 Added 1.96%	23,158 $3.43 Million
Q2 2020 Aug 13, 2020	SELL	$136.42 - $164.18 $25 Million - $30.1 Million	-183,113 Reduced 88.97%	22,712 $3.73 Million
Q1 2020 May 06, 2020	BUY	$119.05 - $147.35 $13.7 Million - $17 Million	115,482 Added 127.83%	205,825 $28.6 Million
Q4 2019 Feb 10, 2020	SELL	$106.92 - $132.43 $5.01 Million - $6.21 Million	-46,865 Reduced 34.16%	90,343 $11.9 Million
Q3 2019 Nov 08, 2019	SELL	$106.79 - $116.16 $5.86 Million - $6.38 Million	-54,886 Reduced 28.57%	137,208 $15.3 Million
Q2 2019 Aug 12, 2019	BUY	$110.79 - $129.32 $1.06 Million - $1.24 Million	9,594 Added 5.26%	192,094 $21.3 Million
Q1 2019 May 13, 2019	BUY	$111.31 - $131.02 $13.2 Million - $15.5 Million	118,495 Added 185.13%	182,500 $23.7 Million
Q4 2018 Feb 13, 2019	SELL	$105.9 - $118.64 $10.6 Million - $11.8 Million	-99,750 Reduced 60.91%	64,005 $7.41 Million
Q3 2018 Nov 06, 2018	SELL	$85.86 - $107.31 $204,861 - $256,041	-2,386 Reduced 1.44%	163,755 $17.6 Million
Q2 2018 Aug 10, 2018	SELL	$75.7 - $86.88 $169,416 - $194,437	-2,238 Reduced 1.33%	166,141 $14.2 Million
Q1 2018 May 07, 2018	BUY	$74.21 - $87.6 $820,762 - $968,855	11,060 Added 7.03%	168,379 $13 Million
Q4 2017 Feb 06, 2018	SELL	$81.94 - $87.89 $1.65 Million - $1.77 Million	-20,171 Reduced 11.36%	157,319 $13.3 Million
Q3 2017 Nov 08, 2017	BUY	$77.07 - $85.54 $13.7 Million - $15.2 Million	177,490	177,490 $15.2 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $740B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.

Account